Alex Kim is Chief Financial Officer of Standard BioTools and has responsibility for Finance, Accounting, IT, and our Legal and Compliance functions. Alex has a passion for improving healthcare and in building businesses by bringing together teams and capabilities to accelerate the pace of innovative breakthroughs. Previously, Alex was Chief Operating Officer.
Prior to joining Standard BioTools, Alex was President of Milliken’s Healthcare Division, a leading provider of advanced wound care products for human health, animal health, and sports medicine. He joined Milliken in 2015 initially as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development at Pall Corporation. And from 2002 to 2012, he worked at Danaher Corporation (NYSE:DHR) in a variety of roles in general management, M&A, and business development. Over his career, Alex has completed over 40 transactions, largely focused on healthcare, medical technology, and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business. In his early career, Alex worked in a variety of engineering design, product development, and marketing/sales support roles. Alex has a BS in Mechanical Engineering from Carnegie Mellon University, an MS In Mechanical Engineering from University of Pittsburgh, and an MBA from Stanford University.
What is Hanjoon Alex Kim's net worth?
The estimated net worth of Hanjoon Alex Kim is at least $888.42 thousand as of May 23rd, 2025. Mr. Kim owns 930,286 shares of Standard BioTools stock worth more than $888,423 as of March 26th. This net worth evaluation does not reflect any other investments that Mr. Kim may own. Learn More about Hanjoon Alex Kim's net worth.
How do I contact Hanjoon Alex Kim?
Has Hanjoon Alex Kim been buying or selling shares of Standard BioTools?
Hanjoon Alex Kim has not been actively trading shares of Standard BioTools over the course of the past ninety days. Most recently, Hanjoon Alex Kim sold 1,428 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $0.94, for a transaction totalling $1,342.32. Following the completion of the sale, the chief financial officer now directly owns 930,286 shares of the company's stock, valued at $874,468.84. Learn More on Hanjoon Alex Kim's trading history.
Who are Standard BioTools' active insiders?
Are insiders buying or selling shares of Standard BioTools?
In the last twelve months, Standard BioTools insiders bought shares 23 times. They purchased a total of 12,458,220 shares worth more than $15,954,696.20. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 58,089 shares worth more than $57,450.84. The most recent insider tranaction occured on December, 4th when Director Casdin Partners Master Fund, L bought 150,000 shares worth more than $217,500.00. Insiders at Standard BioTools own 23.2% of the company.
Learn More about insider trades at Standard BioTools. Information on this page was last updated on 12/4/2025.
